ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2024
A Personalized Dosing Strategy Optimization for Diabetes Management: Applications to Gestational Diabetes Mellitus.
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New PK/PD model directly links diabetes drug dose to blood glucose level for personalized care.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type II diabetes mellitus is a disorder that disrupts the way the body uses glucose. It is managed by close monitoring of blood glucose levels while the clinician experiments with a dosing strategy based on some clinical guidelines and his/her own experience. In this study, we propose a treatment planning model that optimizes the dosing strategy for diabetes treatment. The model utilizes a patient's personalized characteristics of disease progression and dose-response to optimize the drug dosage. Such personalized evidence is estimated by a drug-dose-drug-effect predictive model using the daily blood glucose data recorded during the titration period. We apply these to a group of patients suffering from gestational diabetes. For each patient, drug-dose-drug-effect prediction was established based on the first four weeks of self-monitored blood glucose. The treatment model then individualizes and optimizes the dose regimen based on the patient's personalized drug-dose-drug-effect characteristics. Consistently, the optimized dose regimens use less amount of drug while achieving better glycemic control than the original regimens used to treat the patients. This results in the first mathematical model that is data-driven and evidence-based and that quantitatively optimizes dosage for the treatment of diabetes. The model can generate a personalized dose regimen that has a better treatment outcome and is more drug-efficient. Clinical trials must be conducted to gauge the overall effectiveness.
Indexed as
Identifiers
40417543PMC12099437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.